Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 123-129, 2003.
Article
Dans Coréen
| WPRIM
| ID: wpr-18457
ABSTRACT
PURPOSE:
This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma. MATERIALS ANDMETHODS:
Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1, 000 mg/m2 intravenous (IV) 24 hour infusion (Day 1~3), leucovorin 20 mg/m2 (Day 1~3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks.RESULTS:
The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range 4~24), the median time to response was 8 weeks (range 8~20) the median time to progression was 30.0 weeks (95% CI 16.3~43.2) and the median overall survival duration was 36.0 weeks (95% CI 1.7~70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity.CONCLUSION:
This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs de l'estomac
/
Vomissement
/
Leucovorine
/
Diarrhée
/
Traitement médicamenteux
/
Association de médicaments
/
Inflammation muqueuse
/
Fluorouracil
/
Anémie
/
Nausée
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Cancer Research and Treatment
Année:
2003
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS